BioCentury
ARTICLE | Clinical News

ChronVac-C: Interim Phase II data

April 8, 2013 7:00 AM UTC

Interim data from an open-label, Swedish Phase II trial in 29 treatment-naive patients with chronic HCV genotype 1 infection showed that 2 doses of 500 µg intramuscular ChronVac-C administered 4 weeks apart followed by Pegasys peginterferon alfa-2a and Copegus ribavirin did not significantly improve treatment outcomes at week 12 vs. Pegasys and Copegus alone. Specifically, ChronVac-C plus Pegasys and Copegus led to HCV RNA levels of <15 IU at week 12 in 71% of patients vs. 58% of patients receiving Pegasys and Copegus alone. Additionally, 65% of patients in the ChronVac-C arm were HCV RNA negative at week 12 vs. 58% for Pegasys and Copegus alone. ChronVac-C was safe with no serious adverse events reported. ...